About 17,944 results
Lupus: Using Diet and Nutrition to Improve Symptoms and Outcomes
Rodriguez, T.

Mar 5th, 2017 - A healthy diet is important in general, but perhaps even more so for the roughly 1 million Americans and 3 million people worldwide who suffer from systemic lupus erythematosus (SLE).1 Because of the multifaceted challenges presented by the disease, consuming adequate amounts of the right nutrients — and limiting others — can help relieve symptoms and improve outcomes

Get the Facts: Sugar-Sweetened Beverages and Consumption

Feb 26th, 2017 - Sugar-sweetened beverages (SSBs) or sugary drinks are leading sources of added sugars in the American diet. Frequently drinking sugar-sweetened beverages is associated with weight gain/obesity, type 2 diabetes, heart disease, kidney diseases, non-alcoholic liver disease, tooth decay and cavities, and gout, a type of arthritis.1-4 Limiting the amount of SSB intake can help individuals maintain a...

Systemic Lupus Erythematosus: Primary Care Approach to Diagnosis and Management
American Family Physician;

Aug 14th, 2016 - Systemic lupus erythematosus is an autoimmune disease that affects many systems, including the skin, musculoskeletal, renal, neuropsychiatric, hematologic, cardiovascular, pulmonary, and reproductive systems. Family physicians should be familiar with the manifestations of lupus to aid in early diagnosis, monitoring patients with mild disease, recognizing warning signs that require referral to a...

FDA Grants Breakthrough Therapy Designation for Daiichi Sankyo and Plexxikon's Investigational CSF-1R Inhibitor Pexidartinib (PLX3397) in Tenosynovial Giant Cell Tumo

Oct 10th, 2015 - Daiichi Sankyo, Inc. and Plexxikon Inc., a member of the Daiichi Sankyo Group, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to its investigational oral CSF-1R inhibitor pexidartinib (formerly PLX3397) for the treatment of tenosynovial giant cell tumor (TGCT) where surgical removal of the tumor would be associated with potentially ...

Four Strategies for Managing Opioid-Induced Side Effects in Older Adults
Rogers, E. et. al.

Apr 4th, 2014 - Opioid medications are considered key therapeutic interventions in the management of both acute pain and cancer-related pain among patients of all ages; however, their role in treating patients with chronic noncancer pain remains controversial. While the debate about the appropriate role of opioids in the treatment of chronic pain continues, the fact remains that many clinicians prescribe opioi...

Seasonal Variation in the Activity of Systemic Lupus Erythematosus
Journal of Rheumatology;

May 31st, 2012 - Objective To determine whether there is any seasonal variation in the activity of systemic lupus erythematosus (SLE) overall and by individual organs. Methods The study group comprised 2102 patients with SLE who were followed in a prospective longitudinal cohort study. In this cohort, 92.3% of the patients were women. The mean ± SD age of the patients was 47.9 ± 13.9 years, 56.3% were whit...

Systemic lupus erythematosus in the elderly
Rheumatology International; Achour, A. et. al.

May 1st, 2012 - Onset of the disease above the age of 65 years is unusual. This study was undertaken to determine retrospectively the clinical and laboratory features in SLE patients aged over 65 years. It is a retrospective study about 18 elderly patients with SLE out of 342 diagnosed between 1994 and 2009 in the center of Tunisia. All patients had at least 4 of 11 revised ACR criteria of SLE. The frequency o...

Measures of self‐efficacy: Arthritis Self‐Efficacy Scale (ASES), Arthritis Self‐Efficacy Scale‐8 Item (ASES‐8), Children's Arthritis Self‐Efficacy Scale (CASE), Chronic Disease Self‐Efficacy Scale ...
Arthritis Care & Research; Brady, T.

Nov 6th, 2011 - Enhancing self‐efficacy has become an essential feature of many arthritis management interventions because of its robust relationships with health behaviors and health status. Empirical studies document that self‐efficacy predicts health behaviors such as physical activity, eating behaviors, and pain coping strategies (1). In rheumatoid arthritis and osteoarthritis, self‐efficacy has also been ...

Spinal muscular atrophy
Orphanet Journal of Rare Diseasesvolume;

Nov 2nd, 2011 - Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disease characterized by degeneration of alpha motor neurons in the spinal cord, resulting in progressive proximal muscle weakness and paralysis. Estimated incidence is 1 in 6,000 to 1 in 10,000 live births and carrier frequency of 1/40-1/60. This disease is characterized by generalized muscle weakness and atrophy predominati...

Food of the Gods: Cure for Humanity? A Cultural History of the Medicinal and Ritual Use of Chocolate
Dillinger, T. et. al.

Jul 31st, 2000 - The medicinal use of cacao, or chocolate, both as a primary remedy and as a vehicle to deliver other medicines, originated in the New World and diffused to Europe in the mid 1500s. These practices originated among the Olmec, Maya and Mexica (Aztec). The word cacao is derived from Olmec and the subsequent Mayan languages (kakaw); the chocolate-related term cacahuatl is Nahuatl (Aztec language), ...

PENNSAID (diclofenac sodium)

PENNSAID (diclofenac sodium topical solution) official site. Click to see full safety and prescribing information, including boxed warning.

VIMIZIM® (elosulfase alfa) HCP

VIMIZIM® (elosulfase alfa) is indicated for patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome).

Talk SLE: Systemic Lupus Erythematosus for Rheumatologists

Talk SLE provides resources and information from experts to help rheumatologists and their patients to meet the challenge of systemic lupus erythematosus

EVENITY (romosozumab-aqqg)

EVENITY (romosozumab) is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture

Improving Patient Interactions | Talk SLE

Managing patients with systemic lupus erythematosus requires efforts from a multidisciplinary team. Learn how to improve communication with patients for better disease outcomes.

Resources for Patients with Systemic Lupus Erythematosus & Caregivers | Talk SLE

The need for healthcare providers to effectively engage with patients with SLE is ongoing and the stakes are high. Even when patients have no complaints and no visual signs of disease, organ damage can be occurring. We've developed these tools to help both you and your patients communicate and be vigilant.

Challenges in Diagnosing Systemic Lupus Erythematosus | Talk SLE

More than 60% of patients with SLE report that they were initially misdiagnosed. In fact, accurate diagnosis may take years.

Systemic Lupus Erythematosus Patient Case Studies | Talk SLE

SLE can present in patients in a variety of manifestations.1 It can also have a considerable impact on patients' lives—interpersonal relationships, workplace productivity, and quality of life and well-being

BENLYSTA (belimumab)

BENLYSTA is indicated for the treatment of patients with active, autoantibody-positive, systemic lupus erythematosus (SLE) who receive standard therapy.